Autopsy report · NCT00939276

Macular Edema Incidence/Severity Reduction With Nevanac

“Patient recruitment difficulties”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years before it stopped.
• 175 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Alcon Research

Sponsor type

Industry

Conditions

Diabetic Retinopathy

Interventions

Nepafenac ophthalmic suspension, 0.1% (NEVANAC®); Nepafenac ophthalmic suspension vehicle

Participants

175

Sites

1

Countries

United States

Trials that died the same way

• Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)
  “Difficulties in patient recruitment” (99% match in meaning)
• Tibial Delayed Healing Pivotal Clinical Trial
  “Difficulty in patient recruitment” (98% match in meaning)
• Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
  “Difficulty with patient recruitment” (97% match in meaning)
• Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia
  “Patient recruitment insufficient” (93% match in meaning)
• Electrocochleography Along Cochlear Implant Auditory Rehabilitation
  “patient recruitment problem” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.